1-8 of 8
Selma Ugurel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Interplay between Metabolic Adaptations and Diet in Cancer Immunotherapy

Lena Espelage, Natalie Wagner, Jan-Malte Placke, Selma Ugurel, Alpaslan Tasdogan
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3117–3127.
https://doi.org/10.1158/1078-0432.CCR-22-3468
Published: 01 August 2024
View articletitled, The Interplay between Metabolic Adaptations and Diet in Cancer Immunotherapy
Open the PDF for The Interplay between Metabolic Adaptations and Diet in Cancer Immunotherapy in another window
Journal Articles

Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma

Ivelina Spassova, Selma Ugurel, Patrick Terheyden, Antje Sucker, Jessica C. Hassel, Cathrin Ritter, Linda Kubat, Daniel Habermann, Farnoush Farahpour, Mohammadkarim Saeedghalati, Lukas Peiffer, Rajiv Kumar, David Schrama, Daniel Hoffmann, Dirk Schadendorf, Jürgen C. Becker
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2257–2267.
https://doi.org/10.1158/1078-0432.CCR-19-2244
Published: 01 May 2020
View articletitled, Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma
Open the PDF for Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma

Kaiji Fan, Cathrin Ritter, Paul Nghiem, Astrid Blom, Monique E. Verhaegen, Andrzej Dlugosz, Niels Ødum, Anders Woetmann, Richard W. Tothill, Rodney J. Hicks, Michael Sand, David Schrama, Dirk Schadendorf, Selma Ugurel, Jürgen C. Becker
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5873–5882.
https://doi.org/10.1158/1078-0432.CCR-18-1184
Published: 03 December 2018
View articletitled, Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Open the PDF for Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up

Selma Ugurel, Thomas Mentzel, Jochen Utikal, Peter Helmbold, Peter Mohr, Claudia Pföhler, Meinhard Schiller, Axel Hauschild, Rüdiger Hein, Eckhardt Kämpgen, Ivonne Kellner, Martin Leverkus, Jürgen C. Becker, Philip Ströbel, Dirk Schadendorf
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2): 499–510.
https://doi.org/10.1158/1078-0432.CCR-13-1411
Published: 16 January 2014
View articletitled, Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up
Open the PDF for Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up in another window
Includes: Supplementary data
Journal Articles

Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B

Annette Paschen, Antje Sucker, Bettina Hill, Iris Moll, Marc Zapatka, Xuan Duc Nguyen, Geok Choo Sim, Isabelle Gutmann, Jessica Hassel, Jürgen C. Becker, Alexander Steinle, Dirk Schadendorf, Selma Ugurel
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5208–5215.
https://doi.org/10.1158/1078-0432.CCR-09-0886
Published: 12 August 2009
View articletitled, Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B
Open the PDF for Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B in another window
Journal Articles

Microphthalmia-Associated Transcription Factor Gene Amplification in Metastatic Melanoma Is a Prognostic Marker for Patient Survival, But Not a Predictive Marker for Chemosensitivity and Chemotherapy Response

Selma Ugurel, Roland Houben, David Schrama, Heike Voigt, Marc Zapatka, Dirk Schadendorf, Eva B. Bröcker, Jürgen C. Becker
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6344–6350.
https://doi.org/10.1158/1078-0432.CCR-06-2682
Published: 01 November 2007
View articletitled, Microphthalmia-Associated Transcription Factor Gene Amplification in Metastatic Melanoma Is a Prognostic Marker for Patient Survival, But Not a Predictive Marker for Chemosensitivity and Chemotherapy Response
Open the PDF for Microphthalmia-Associated Transcription Factor Gene Amplification in Metastatic Melanoma Is a Prognostic Marker for Patient Survival, But Not a Predictive Marker for Chemosensitivity and Chemotherapy Response in another window
Journal Articles

In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group

Selma Ugurel, Dirk Schadendorf, Claudia Pföhler, Karsten Neuber, Adina Thoelke, Jens Ulrich, Axel Hauschild, Konstanze Spieth, Martin Kaatz, Werner Rittgen, Stefan Delorme, Wolfgang Tilgen, Uwe Reinhold
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (18): 5454–5463.
https://doi.org/10.1158/1078-0432.CCR-05-2763
Published: 25 September 2006
View articletitled, In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group
Open the PDF for In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group in another window
Includes: Supplementary data
Journal Articles

Increased Soluble CD95 (sFas/CD95) Serum Level Correlates with Poor Prognosis in Melanoma Patients

Selma Ugurel, Gunter Rappl, Wolfgang Tilgen, Uwe Reinhold
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (5): 1282–1286.
Published: 01 May 2001
View articletitled, Increased Soluble CD95 (sFas/CD95) Serum Level Correlates with Poor Prognosis in Melanoma Patients
Open the PDF for Increased Soluble CD95 (sFas/CD95) Serum Level Correlates with Poor Prognosis in Melanoma Patients in another window